Peficitinib

Peficitinib is an oral Janus kinase inhibitor developed by Astellas Pharma for the treatment of rheumatoid arthritis. It is currently approved for use in Japan and is undergoing clinical trials in other countries.

Mechanism of Action

Peficitinib works by inhibiting the Janus kinase (JAK) family of enzymes, which are involved in the signaling pathways of various cytokines and growth factors that are important for hematopoiesis and immune cell function. By inhibiting these enzymes, peficitinib can reduce inflammation and other symptoms of rheumatoid arthritis.

Clinical Trials

Peficitinib has undergone several clinical trials to evaluate its safety and efficacy in treating rheumatoid arthritis. In a Phase 3 trial conducted in Japan, peficitinib was found to be effective in reducing the signs and symptoms of rheumatoid arthritis, and had a safety profile consistent with other JAK inhibitors.

Side Effects

Common side effects of peficitinib include nausea, diarrhea, and upper respiratory tract infection. Serious side effects can include anemia, neutropenia, and thrombocytopenia. Patients taking peficitinib should be monitored for these and other potential side effects.

See Also

• Janus kinase inhibitor
• Rheumatoid arthritis
• Astellas Pharma

References

<references />

This article is a medical stub. You can help WikiMD by expanding it!
Most recent articles Ongoing trials	Wikipedia